Interindividual Genetic Variability as a Determinant of Chemotherapy Toxicity and Response in Pediatric Bone Marrow Transplantation Patients

The title of this study is interindividual genetic variability as a determinant of
chemotherapy toxicity and response in pediatric oncology/bone marrow transplantation
patients. We will collect blood from pediatric oncology/bone marrow transplantation patients
who are going to receive chemotherapy in order to assess several defined genetic
polymorphisms that may be involved in chemotherapy toxicity and response. The polymorphisms
will be assessed on normal mononuclear cells by a combination of techniques. We will
determine whether these polymorphisms occur in pediatric oncology/bone marrow transplantation
patients and their correlation with different clinical features during and following therapy
including toxicity and response. The presence or absence of polymorphisms will be correlated
with patient outcome and tumor recurrence.

Inclusion Criteria:

- All Pediatric Oncology and Bone Marrow Transplantation Service patients with a
histologically proven tumor for whom there is an intent to treat with chemotherapy are
eligible for participation in this study. The patient does not need to be newly
diagnosed for enrollment on this protocol.

- All patients or their guardians must provide written informed consent. Minors will be
required to provide assent.

Exclusion Criteria: